Back to top
more

NGM BIOPHARMACT (NGM)

(Delayed Data from NSDQ)

$15.91 USD

15.91
178,737

-0.04 (-0.25%)

Updated May 3, 2019 04:00 PM ET

After-Market: $15.70 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

NGM Biopharmaceuticals (NGM) Reports Q4 Loss, Lags Revenue Estimates

NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of 10.81% and 91.75%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Why NGM Biopharmaceuticals (NGM) Might Surprise This Earnings Season

NGM Biopharmaceuticals (NGM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

NGM Biopharmaceuticals (NGM) Reports Q3 Loss, Misses Revenue Estimates

NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of 12.50% and 67.67%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Strength Seen in Repare Therapeutics Inc. (RPTX): Can Its 12.2% Jump Turn into More Strength?

Repare Therapeutics Inc. (RPTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

NGM Biopharmaceuticals (NGM) Reports Q2 Loss, Misses Revenue Estimates

NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of 0% and 42.30%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Nurix Therapeutics, Inc. (NRIX) Reports Q2 Loss, Tops Revenue Estimates

Nurix Therapeutics, Inc. (NRIX) delivered earnings and revenue surprises of 28.57% and 39.67%, respectively, for the quarter ended May 2023. Do the numbers hold clues to what lies ahead for the stock?

NGM Biopharmaceuticals (NGM) Reports Q1 Loss, Misses Revenue Estimates

NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of -11.54% and 67.55%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate ADC Therapeutics SA (ADCT) to Report a Decline in Earnings: What to Look Out for

ADC Therapeutics SA (ADCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

NGM Biopharmaceuticals (NGM) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

NGM Biopharmaceuticals (NGM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

NGM Biopharmaceuticals (NGM) Reports Q4 Loss, Tops Revenue Estimates

NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of 13.46% and 166.31%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

How Much Upside is Left in NGM Biopharmaceuticals (NGM)? Wall Street Analysts Think 462%

The mean of analysts' price targets for NGM Biopharmaceuticals (NGM) points to a 461.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

NGM Biopharmaceuticals (NGM) Reports Q3 Loss, Tops Revenue Estimates

NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of 3.28% and 12.66%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

After Plunging 59.4% in 4 Weeks, Here's Why the Trend Might Reverse for NGM Biopharmaceuticals (NGM)

The heavy selling pressure might have exhausted for NGM Biopharmaceuticals (NGM) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Cara Therapeutics (CARA) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Cara (CARA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

NGM Biopharmaceuticals (NGM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

NGM Biopharmaceuticals (NGM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

After Plunging 76.6% in 4 Weeks, Here's Why the Trend Might Reverse for NGM Biopharmaceuticals (NGM)

NGM Biopharmaceuticals (NGM) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

NGM Biopharmaceuticals (NGM) Reports Q2 Loss, Misses Revenue Estimates

NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of -7.27% and 37.94%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Bluebird Bio (BLUE) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Bluebird (BLUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: NGM Biopharmaceuticals (NGM) Q2 Earnings Expected to Decline

NGM Biopharmaceuticals (NGM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

NGM Biopharmaceuticals (NGM) Soars 6.8%: Is Further Upside Left in the Stock?

NGM Biopharmaceuticals (NGM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

NGM Biopharmaceuticals (NGM) Reports Q1 Loss, Lags Revenue Estimates

NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of 0% and 6.26%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q1 Loss, Tops Revenue Estimates

Deciphera Pharmaceuticals, Inc. (DCPH) delivered earnings and revenue surprises of 4.76% and 7.47%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

NGM Biopharmaceuticals (NGM) Reports Q4 Loss, Tops Revenue Estimates

NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of 5.41% and 4.10%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Intra-Cellular Therapies (ITCI) Reports Q4 Loss, Tops Revenue Estimates

Intra-Cellular (ITCI) delivered earnings and revenue surprises of 0% and 3.58%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

NGM Bio (NGM) Up on Fast Track Tag For Ophthalmology Drug

The FDA bestows a Fast Track designation to NGM Bio's (NGM) product candidate, NGM621, for treating patients with geographic atrophy secondary to age-related macular degeneration. Stock up.